PRNewsWire·Jun 22, 2026
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd.(GLMD)Earnings, Financials & Key Ratios
GLMD•NASDAQ
$0.56
Price updated Jul 6, 2026
AboutGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Show more
- Revenue$0
- EBITDA-$9M-37.4%
- Net Income-$10M-37.1%
- EPS (Diluted)-2.39+70.4%
- ROE-64.21%-29.0%
GLMD Price & Volume
Galmed Pharmaceuticals Ltd. (GLMD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Operational Viability
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent insolvency and dilution
Key Thesis Takeaways
- Galmed Pharmaceuticals remains a pre-commercial entity with no recurring revenue, relying entirely on external capital to fund its clinical development pipeline.
- The company faces significant financial pressure as evidenced by a $4.8M net loss in 2025Q4 and a rapidly depleting cash position of $4.0M.
- Investors should monitor the binary risk profile, as the lack of tangible assets and persistent equity erosion suggest a precarious path toward long-term sustainability.
Verdict Logic
the company's $4.0M cash balance appears insufficient to support ongoing clinical operations given the $1.9M free cash flow burn recorded in 2025Q4.
GLMD Growth Metrics
Galmed Pharmaceuticals Ltd. (GLMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.95%
Return on Capital
10 Years-60.84%
5 Years-63.36%
3 Years-49.79%
Last Year-53.01%
GLMD Recent Earnings
Galmed Pharmaceuticals Ltd. (GLMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.92-142.1%
$0.38
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.80-56.9%
$0.51
Rev
—
$1M
Q4 2025
Nov 26, 2025Metric
Actual
Est
EPS
$0.33+38.9%
$0.54
Rev
—
$1M
Q3 2025
Aug 28, 2025Metric
Actual
Est
EPS
$0.63+175.9%
$0.83
Rev
—
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.92vs $0.38-142.1% | — |
| Q2 2026 | Mar 31, 2026 | $0.80vs $0.51-56.9% | —vs $1M |
| Q4 2025 | Nov 26, 2025 | $0.33vs $0.54+38.9% | —vs $1M |
| Q3 2025 | Aug 28, 2025 | $0.63vs $0.83+175.9% | —vs $1M |
Based on last 12 quarters of dataView full earnings history →
Latest GLMD News
Recent stock market news and headlines for Galmed Pharmaceuticals Ltd. (GLMD)
Peers Comparison
Key metrics vs top competitors for Galmed Pharmaceuticals Ltd. (GLMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.56 | $3.05M | -0.23 | — | — | -64.21% | — | |
| $529.48 | $12.21B | -41.20 | 432.05% | -27.32% | -50.15% | — | |
| $1.30 | $348.74M | -62.50 | 47.46% | -8.83% | -62.72% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $31.50 | $3.86B | 18.75 | 19.78% | 37.08% | 23.65% | — | |
| $8.95 | $447.53M | 256.88 | 134.56% | -14.12% | -22.98% | — |
Compare GLMD vs Peers
Galmed Pharmaceuticals Ltd. (GLMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GLMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GLMD Frequently Asked Questions
Galmed Pharmaceuticals Ltd. (GLMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GLMD profitable?
Galmed Pharmaceuticals Ltd. (GLMD) reported a net loss of $10.3M for fiscal year 2025.
Dividend & Returns
What is GLMD's return on equity?
Galmed Pharmaceuticals Ltd. (GLMD) has a return on equity (ROE) of -64.2%. Negative ROE indicates the company is unprofitable.
What is Galmed Pharmaceuticals Ltd.'s free cash flow?
Galmed Pharmaceuticals Ltd. (GLMD) had negative free cash flow of $6.3M in fiscal year 2025, likely due to heavy capital investments.